MedTrace Logo

CC100: Safety and Tolerability of Single Doses

NCT02050334 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in increasing doses. How long the drug remains in the body will also be calculated.

Conditions

  • Healthy

Interventions

DRUG

CC100

CC100 reconstituted in diluent

DRUG

Placebo

Diluent. Amount to match CC100 dose.

Sponsors & Collaborators

  • Chemigen, LLC

    lead INDUSTRY

Principal Investigators

  • Robert M Pascuzzi, MD · IU Health Physicians - Neurology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-07-31
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02050334 on ClinicalTrials.gov